Clene (NASDAQ:CLNN) Full Year 2022 Results
Key Financial Results
- Net loss: US$29.9m (loss widened by 207% from FY 2021).
- US$0.46 loss per share (further deteriorated from US$0.16 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Clene Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 39%. Earnings per share (EPS) also surpassed analyst estimates by 20%.
Looking ahead, revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Clene (at least 2 which are a bit concerning), and understanding them should be part of your investment process.
Valuation is complex, but we're here to simplify it.
Discover if Clene might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.